Next-generation sequencing in breast cancer: First take home messages

Current Opinion in Oncology

Volumn 24, Issue 6, 2012, Pages 597-604

  Desmedt, Christine ^a   Voet, Thierry ^b,c   Sotiriou, Christos ^a   Campbell, Peter J ^c  

^a JULES BORDET INSTITUTE   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

Author keywords

breast cancer; cancer genes; driver passenger mutations; next generation sequencing; tumor heterogeneity

Indexed keywords

ADENOSINE DEAMINASE; BRCA1 PROTEIN; BRCA2 PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; TRANSCRIPTION FACTOR TWIST;

ALTERNATIVE RNA SPLICING; BREAST CANCER; CANCER GROWTH; DNA SEQUENCE; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION PROFILING; GENE MUTATION; GENE REARRANGEMENT; GENE SEQUENCE; GENETIC HETEROGENEITY; GENETIC IDENTIFICATION; GENOME; GENOMIC INSTABILITY; GERM LINE; HUMAN; MICROARRAY ANALYSIS; NEXT GENERATION SEQUENCING; PASSENGER MUTATION; PATIENT MONITORING; PERSONALIZED MEDICINE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PYROSEQUENCING; REVIEW; RNA SEQUENCE; SOMATIC MUTATION; TREATMENT RESPONSE; TUMOR GENE;

BREAST NEOPLASMS; DATABASES, GENETIC; FEMALE; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION STUDIES; GENETIC HETEROGENEITY; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; INDIVIDUALIZED MEDICINE; SEQUENCE ANALYSIS, DNA; SEQUENCE ANALYSIS, RNA;

EID: 84868210526     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328359554e     Document Type: Review

References (27)

1. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009; 360:790-800.
2. Chin L, Hahn WC, Getz G, et al. Making sense of cancer genomic data. Genes Dev 2011; 25:534-555.
3. Meldrum C, Doyle MA, Tothill RW. Next-generation sequencing for cancer diagnostics: a practical perspective. Clin Biochem Rev 2011; 32:177-195.
4. Xu X, Hou Y, Yin X, et al. Single-cell exome sequencing reveals singlenucleotide mutation characteristics of a kidney tumor. Cell 2012; 148:886-895.
5. Hou Y, Song L, Zhu P, et al. Single-cell exome sequencing and monoclonal evolution of a JAK2-negative myeloproliferative neoplasm. Cell 2012; 148:873-885.
6. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57-70.
7. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144:646-674.
8. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature 2009; 458:719-724.
9. Shah SP, Roth A, Goya R, et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012.
10. Ellis MJ, Ding L, Shen D, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 2012; 486:353-360.
11. Stephens PJ, Tarpey PS, Davies H, et al. The landscape of cancer genes and mutational processes in breast cancer. Nature 2012; 486:400-404.
12. Banerji S, Cibulskis K, Rangel-Escareno C, et al. Sequence analysis of mutations and translocations across breast cancer subtypes. Nature 2012; 486:405-409.
13. Ignatiadis M, Singhal SK, Desmedt C, et al. Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. J Clin Oncol 2012; 30:1996-2004.
14. Desmedt C, Haibe-Kains B, Wirapati P, et al. Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes. Clin Cancer Res 2008; 14:5158-5165.
15. Wang Z, Gerstein M, Snyder M. RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet 2009; 10:57-63.
16. Loman NJ, Misra RV, Dallman TJ, et al. Performance comparison of benchtop high-throughput sequencing platforms. Nat Biotechnol 2012; 30:434-439.
17. Shah SP, Morin RD, Khattra J, et al. Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 2009; 461:809-813.
18. Shapiro IM, Cheng AW, Flytzanis NC, et al. An EMT-driven alternative splicing program occurs in human breast cancer and modulates cellular phenotype. PLoS Genet 2011; 7:e1002218.
19. Nik-Zainal S, Alexandrov LB, Wedge DC, et al. Mutational processes molding the genomes of 21 breast cancers. Cell 2012; 149:979-993.
20. Nik-Zainal S, Van Loo P, Wedge DC, et al. The life history of 21 breast cancers. Cell 2012; 149:994-1007.
21. Stephens PJ, McBride DJ, Lin ML, et al. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 2009; 462:1005-1010.
22. Leary RJ, Kinde I, Diehl F, et al. Development of personalized tumor biomarkers using massively parallel sequencing. Sci Transl Med 2010; 2:20ra14.
23. McBride DJ, Orpana AK, Sotiriou C, et al. Use of cancer-specific genomic rearrangements to quantify disease burden in plasma from patients with solid tumors. Genes Chromosomes Cancer 2010; 49:1062-1069.
24. Hudson TJ, Anderson W, Artez A, et al. International network of cancer genome projects. Nature 2010; 464:993-998.
25. Forbes SA, Tang G, Bindal N, et al. COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer. Nucleic Acids Res 2009; 38:D652-D657.
26. Loman NJ, Misra RV, Dallman TJ, et al. Performance comparison of benchtop high-throughput sequencing platforms. Nat Biotechnol 2012; 30:562.
27. Lipson D, Capelletti M, Yelensky R, et al. Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies. Nat Med 2012; 18:382-384.